Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - aspirin, quantity: 100 mg; clopidogrel hydrogen sulfate, quantity: 97.875 mg (equivalent: clopidogrel, qty 75 mg) - tablet, film coated - excipient ingredients: hyprolose; hydrogenated castor oil; carnauba wax; stearic acid; colloidal anhydrous silica; microcrystalline cellulose; macrogol 6000; mannitol; maize starch; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide red - clopidogrel winthrop plus aspirin is a fixed-dose combination product intended as continuation of therapy in patients with acute coronary syndrome already initiated with separate clopidogrel and aspirin products: unstable angina or non-st-elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). clopidogrel winthrop plus aspirin is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent). st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, clopidogrel winthrop plus aspirin has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - aspirin, quantity: 100 mg; clopidogrel hydrogen sulfate, quantity: 97.875 mg (equivalent: clopidogrel, qty 75 mg) - tablet, film coated - excipient ingredients: hyprolose; mannitol; carnauba wax; colloidal anhydrous silica; maize starch; microcrystalline cellulose; hydrogenated castor oil; stearic acid; macrogol 6000; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide red - coplavix is a fixed-dose combination product intended as continuation of therapy in patients with acute coronary syndrome already initiated with separate clopidogrel and aspirin products: unstable angina or non-st-elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). coplavix is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent). st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, coplavix has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - morphine sulfate pentahydrate, quantity: 60 mg - tablet, modified release - excipient ingredients: lactose monohydrate; magnesium stearate; hypromellose; povidone; hyetellose; purified talc; titanium dioxide; sunset yellow fcf aluminium lake; macrogol 400 - for the management of severe pain where other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and the pain is opioid-responsive, and requires daily, continuous, long-term treatment. is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. is not indicated as an as-needed (prn) analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - morphine sulfate pentahydrate, quantity: 10 mg/ml - injection, suspension - excipient ingredients: dioleoylphosphatidylcholine; dipalmitoylphosphatidylglycerol; cholesterol; triolein; tricaprylin; sodium chloride; dilute hydrochloric acid; water for injections - for the relief of post-operative pain following major orthopaedic, abdominal, or pelvic surgery via the lumbar epidural route at a maximum recommended dose of 10 mg. appropriate monitoring must be maintained for at least 48 hours - see precautions.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - aluminium sulfate hydrate 20%{relative} (37.3% al sulph (tech. fe free) content 55% =20.5% al sulph);  ;   - topical spray - 20% w/v - active: aluminium sulfate hydrate 20%{relative} (37.3% al sulph (tech. fe free) content 55% =20.5% al sulph)     excipient: gardinol esb water - calms and soothes the pain, itch and swelling of stings and bites.

Australia - English - Department of Health (Therapeutic Goods Administration)

medtronic australasia pty ltd - aluminium sulfate hydrate -

Ireland - English - HPRA (Health Products Regulatory Authority)

penn pharmaceuticals ltd - aluminium sulfate acetic acid l-tartaric acid calcium carbonate purified water -

Israel - English - Ministry of Health

trupharm marketing 1985 ltd. - aluminium chloride hexahydrate - solution - aluminium chloride hexahydrate 20 %w/v - aluminium chlorohydrate - aluminium chlorohydrate - for the topical treatment of hyperhydrosis specifically involving axillae, hands or feet.

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - aspirin,clopidogrel hydrogen sulfate -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - aspirin,clopidogrel hydrogen sulfate -